Non-Invasive Evaluation Of Cardiac Time Intervals By The Hemotag (Tm) Recording Device To Tailor Treatment Of Acutely Decompensated Heart Failure

Introduction Evaluation of cardiac time intervals (CTIs) by the HEMOTAGTM recording device has been associated with early and accurate identification of acutely decompensated heart failure (ADHF). It is unclear if the daily evaluation of CTIs can guide treatment for patients with ADHF and improve short-term outcomes. Methods HATS OFF ( H emotag A ssessmen T for S hort-term O utcomes o F heart F ailure) is a prospective, unblinded, single-center, non-randomized study that enrolled hospitalized patients with ADHF and other acute medical conditions (control group) to assess the relationship between daily isovolumetric contraction time (IVCTs) by HEMOTAGTM and the clinical progression of ADHF. Results A subset analysis of 30 patients admitted between 08/2019 and 12/2019 to our cardiovascular center was performed. Out of these, 12 patients have ADHF, and 18 patients were in the control group. IVCTs were recorded on admission and on a daily basis (during hospitalization) while NT-pro-BNP was collected on admission and on the 3rd day of hospitalization. For patients with ADHF, the initial NT-pro-BNP went from a mean of 5,515 ± 2,766 pg/ml to a mean 3,801± 3,066 pg/ml vs. in the control arm, went from a mean of 130±72 pg/ml to a mean of 149 ±71 pg/ml. The HEMOTAGTM was used to track daily IVCTs (normal Conclusion This study suggests that daily IVCTs by HEMOTAGTM can predict the progression and volume status of patients with ADHF. The applicability of this study to our daily practice and its role that guide treatment will be tested on phase 3 clinical trial (HATS OFF study group). NHLBI grant# R44HL145941 .